Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a cluster randomised controlled trial (FIAT)

Stefan Priebe, Alexandra Burton, Deborah Ashby, Richard Ashcroft, Tom Burns, Anthony David, Sandra Eldridge, Mike Firn, Martin Knapp, Rose McCabe, Stefan Priebe, Alexandra Burton, Deborah Ashby, Richard Ashcroft, Tom Burns, Anthony David, Sandra Eldridge, Mike Firn, Martin Knapp, Rose McCabe

Abstract

Background: Various interventions have been tested to achieve adherence to anti-psychotic maintenance medication in non-adherent patients with psychotic disorders, and there is no consistent evidence for the effectiveness of any established intervention. The effectiveness of financial incentives in improving adherence to a range of treatments has been demonstrated; no randomised controlled trial however has tested the use of financial incentives to achieve medication adherence for patients with psychotic disorders living in the community.

Methods/design: In a cluster randomised controlled trial, 34 mental health teams caring for difficult to engage patients in the community will be randomly allocated to either the intervention group, where patients will be offered a financial incentive for each anti-psychotic depot medication they receive over a 12 month period, or the control group, where all patients will receive treatment as usual. We will recruit 136 patients with psychotic disorders who use these services and who have problems adhering to antipsychotic depot medication, although all conventional methods to achieve adherence have been tried. The primary outcome will be adherence levels, and secondary outcomes are global clinical improvement, number of voluntary and involuntary hospital admissions, number of attempted and completed suicides, incidents of physical violence, number of police arrests, number of days spent in work/training/education, subjective quality of life and satisfaction with medication. We will also establish the cost effectiveness of offering financial incentives.

Discussion: The study aims to provide new evidence on the effectiveness and cost effectiveness of offering financial incentives to patients with psychotic disorders to adhere to antipsychotic maintenance medication. If financial incentives improve adherence and lead to better health and social outcomes, they may be recommended as one option to improve the treatment of non-adherent patients with psychotic disorders.

Trial registration: Current controlled trials ISRCTN77769281.

Figures

Figure 1
Figure 1
This figure displays the CONSORT Flow Diagram.

References

    1. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. Scientific review. JAMA. 2002;288:2868–2879. doi: 10.1001/jama.288.22.2868.
    1. Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry. 2003;183:197–206. doi: 10.1192/bjp.183.3.197.
    1. Giuffrida A, Togerson DJ. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ. 1997;315:703–707.
    1. Carey KB, Carey MP. Enhancing the treatment attendance of mentally ill chemical abusers. Journal of Behaviour Therapy and Experimental Psychiatry. 1990;21:205–209. doi: 10.1016/0005-7916(90)90008-9.
    1. Helmus TC, Schoener RP, Saules KK, Roll JM. Reinforcement of counselling attendance and alcohol abstinence in a community-based dual-diagnosis treatment program: a feasibility study. Psychol Addict Behav. 2003;17:249–251. doi: 10.1037/0893-164X.17.3.249.
    1. Messina N, Farabee D, Rawson R. Treatment Responsivity of Cocaine-Dependent Patients With Antisocial Personality Disorder to Cognitive-Behavioral and Contingency Management Interventions. J Consult Clin Psychol. 2003;71:320–329. doi: 10.1037/0022-006X.71.2.320.
    1. Post EP, Cruz M, Harman J. Incentive Payments for Attendance at Appointments for Depression Among Low-Income African Americans. Psychiatr Serv. 2006;57:414–416. doi: 10.1176/appi.ps.57.3.414.
    1. Roll JM, Higgins ST, Steingard S, McGinley M. Use of Monetary Reinforcement to Reduce the Cigarette Smoking of Persons With Schizophrenia: Feasibility Study. Exp Clin Psychopharmacol. 1998;6:157–161. doi: 10.1037/1064-1297.6.2.157.
    1. Roll LM, Chermack ST, Chudzynski JE. Investigating the use of contingency management of cocaine abuse among individuals with schizophrenia: a feasibility study. Psychiatry Res. 2004;125:61–64. doi: 10.1016/j.psychres.2003.10.003.
    1. Shaner A, Roberts LJ, Eckman TA. Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr Serv. 1997;48:807–810.
    1. Sigmon SC, Steingard S, Badger GJ, Anthony SL, Higgins ST. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Exp Clin Psychopharmacol. 2000;8:509–517. doi: 10.1037/1064-1297.8.4.509.
    1. Thyer BA, Irvine S, Santa CA. Contingency management of exercise by chronic schizophrenics. Percept Mot Skills. 1984;58:419–25.
    1. Tidey JW, O'Neill SC, Higgins ST. Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Exp Clin Psychopharmacol. 2002;10:241–247. doi: 10.1037/1064-1297.10.3.241.
    1. Tracy K, Babuscio T, Nich C, Kiluk B, Carroll KM, Petry NM, Rounsaville BJ. Contingency management to reduce substance use in individuals who are homeless with co-occurring psychiatric disorders. Am J Drug Alcohol Abuse. 2007;33:253–258. doi: 10.1080/00952990601174931.
    1. Olson PR, Greenberg DJ. Effects of contingency-contracting and decision-making groups with chronic mental patients. J Consult Clin Psychol. 1972;38:376–383. doi: 10.1037/h0032910.
    1. Drebbing CE, Van Ormer A, Krebs C, Rosenheck R, Rounsaville B, Herz L, Penk W. The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. J Appl Behav Anal. 2005;38:359–372. doi: 10.1901/jaba.2005.100-03.
    1. Claassen D, Fakhoury WK, Ford R, Priebe S. Money for medication: Financial incentives to improve medication adherence in assertive outreach. Psychiatr Bull R Coll Psychiatr. 2007;31:4–7. doi: 10.1192/pb.31.1.4.
    1. Claassen D. Financial incentives for antipsychotic depot medication: ethical issues. J Med Ethics. 2007;33:189–193. doi: 10.1136/jme.2006.016188.
    1. Beauchamp TL. Methods and principles in biomedical ethics. J Med Ethics. 2003;29:269–74. doi: 10.1136/jme.29.5.269.
    1. Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90:229–237. doi: 10.1016/j.schres.2006.11.015.
    1. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ No ADM 76-338) National Institute of Mental Health: Rockville, MD; 1976. pp. 218–222.
    1. Priebe S, McCabe R, Bullenkamp J, et al. Structured patient-clinician communication and one-year outcome in community mental health care: A cluster randomised controlled trial. Br J Psychiatry. 2007;191:420–426. doi: 10.1192/bjp.bp.107.036939.
    1. Gharabawi GM, Greenspan A, Rupnow MFT, Kosik-Gonzalez C, Bossie CA, Zhu Y, Kalali AH, Awad AG. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia. BMC Psychiatry. 2006;20:45. doi: 10.1186/1471-244X-6-45.
    1. Mangalore R, Knapp M, Jenkins R. Income-related inequality in mental health in Britain: the concentration index approach. Psychol Med. 2007;37:1037–1045. doi: 10.1017/S003329170600969X.
    1. Eldridge S, Ashby D. Statistical Concepts (Master Classes in Primary Care Research) (No 3) London: Royal College of General Practitioners; 2000.
    1. Eldridge S, Ashby D, Kerry S. Sample size for cluster randomised trials: effects of coefficient of variation of cluster size and analysis method. Int J Epidemiol. 2006;35:1292–1300. doi: 10.1093/ije/dyl129.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit